Skip to main content

Peer Review reports

From: Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series

Original Submission
15 Mar 2021 Submitted Original manuscript
13 Apr 2021 Reviewed Reviewer Report - Binny Khandakar
17 Apr 2021 Reviewed Reviewer Report - Dipin Jayaprakash
17 Jun 2021 Author responded Author comments - Mina Nikanjam
Resubmission - Version 2
17 Jun 2021 Submitted Manuscript version 2
21 Jun 2021 Reviewed Reviewer Report - Binny Khandakar
27 Jul 2021 Reviewed Reviewer Report - Dipin Jayaprakash
9 Sep 2021 Author responded Author comments - Mina Nikanjam
Resubmission - Version 3
9 Sep 2021 Submitted Manuscript version 3
12 Sep 2021 Reviewed Reviewer Report - Dipin Jayaprakash
2 Oct 2021 Reviewed Reviewer Report - Binny Khandakar
6 Dec 2021 Author responded Author comments - Mina Nikanjam
Resubmission - Version 4
6 Dec 2021 Submitted Manuscript version 4
22 Dec 2021 Reviewed Reviewer Report - Kenji Gonda
27 Dec 2021 Reviewed Reviewer Report - Binny Khandakar
25 Apr 2022 Author responded Author comments - Mina Nikanjam
Resubmission - Version 5
25 Apr 2022 Submitted Manuscript version 5
12 Jun 2022 Reviewed Reviewer Report - Kenji Gonda
18 Jun 2022 Reviewed Reviewer Report - Binny Khandakar
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
19 Jul 2022 Editorially accepted
31 Aug 2022 Article published 10.1186/s13256-022-03536-y

You can find further information about peer review here.

Back to article page